Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Publications

Rubatt, JM, Secord, AA, Iversen, E, Grace, L, Soper, W, and Berchuck, A. "Regulation of angiogenic gene expression in p53 wild type and mutant ovarian cancer cells by hypoxia and radiation." GYNECOLOGIC ONCOLOGY 108, no. 3 (March 2008): S84-S84.

Scholars@Duke

Shafer, A, Rubatt, JM, Ayeni, T, Deal, AM, Secord, AA, Soper, JT, Havrilesky, LJ, Van Le, L, and Gehring, PA. "Surgical cytoreduction and dose intensity of adjuvant paclitaxel and carboplatin chemotherapy in advanced epithelial ovarian cancer." March 2008.

Scholars@Duke

Kirkpatrick, JP, Rabbani, ZN, Bentley, RC, Hardee, ME, Karol, S, Meyer, J, Oosterwijk, E, Havrilesky, L, Secord, AA, Vujaskovic, Z, Dewhirst, MW, and Jones, EL. "Elevated CAIX Expression is Associated with an Increased Risk of Distant Failure in Early-Stage Cervical Cancer. (Published online)" Biomark Insights 3 (February 1, 2008): 45-55.

Scholars@Duke

Greer, BE, Koh, W-J, Abu-Rustum, N, Bookman, MA, Bristow, RE, Campos, S, Cho, KR, Copeland, L, Eifel, P, Huh, WK, Jaggernauth, W, Kapp, DS, Kavanagh, J, Lipscomb, GH, Lurain, JR, Morgan, M, Morgan, RJ, Powell, CB, Remmenga, SW, Reynolds, RK, Secord, AA, Small, W, Teng, N, and National Comprehensive Cancer Network, . "Cervical cancer." J Natl Compr Canc Netw 6, no. 1 (January 2008): 14-36.

Scholars@Duke

Jewell, EL, Kulasingam, S, Myers, ER, Alvarez Secord, A, and Havrilesky, LJ. "Primary surgery versus chemoradiation in the treatment of IB2 cervical carcinoma: a cost effectiveness analysis." Gynecol Oncol 107, no. 3 (December 2007): 532-540.

Full Text

Havrilesky, LJ, Secord, AA, Kulasingam, S, and Myers, E. "Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis." Gynecol Oncol 107, no. 2 (November 2007): 211-218.

Full Text

Alvarez Secord, A, Havrilesky, LJ, Bae-Jump, V, Chin, J, Calingaert, B, Bland, A, Rutledge, TL, Berchuck, A, Clarke-Pearson, DL, and Gehrig, PA. "The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer." Gynecol Oncol 107, no. 2 (November 2007): 285-291.

Full Text

Rankins, NC, Secord, AA, Jewell, E, Havrilesky, LJ, Soper, JT, and Myers, E. "Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer." Gynecol Oncol 106, no. 2 (August 2007): 388-393.

Full Text

Secord, AA, Darcy, KM, Hutson, A, Lee, PS, Havrilesky, LJ, Grace, LA, Berchuck, A, and Gynecologic Oncology Group study, . "Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study." Gynecol Oncol 106, no. 1 (July 2007): 221-232.

Full Text

Mutch, DG, Orlando, M, Goss, T, Teneriello, MG, Gordon, AN, McMeekin, SD, Wang, Y, Scribner, DR, Marciniack, M, Naumann, RW, and Secord, AA. "Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 25, no. 19 (July 2007): 2811-2818.

Full Text

Pages